LLY Eli Lilly and Company

Eli Lilly is one of the largest pharmaceutical companies in the world, headquartered in Indianapolis, Indiana. They make medicines that treat serious conditions — most famously, a class of injectable drugs that help people with type 2 diabetes and obesity by regulating hunger hormones in a way that causes significant weight loss. These treatments have been extraordinarily successful: Lilly's annual revenue has roughly doubled in just a few years, reaching about $70 billion. Beyond obesity and diabetes, the company also makes treatments for breast cancer, inflammatory skin conditions, and neurological diseases, employing tens of thousands of people globally.

What makes Lilly uniquely compelling right now is the sheer size of the obesity opportunity. About 40% of American adults have obesity, and for the first time there are medicines that actually work well at treating it — Lilly makes two of the leading ones. The company is spending billions of dollars to build new factories fast enough to meet demand, which squeezes today's profits but positions them for enormous long-term revenue. On top of that, Lilly has one of the industry's deepest research pipelines, including next-generation obesity and diabetes treatments, experimental heart disease drugs, and a recently approved oral version of its flagship treatment that may reach even more patients.

The biggest risk is concentration: roughly three-quarters of Lilly's estimated equity value comes from its diabetes and obesity franchise. If a competing drug proves more effective, if pricing pressure intensifies, or if the obesity market grows more slowly than expected, the stock could fall sharply. Patent timing is another key variable — estimates of how long the franchise stays protected range from the mid-2030s to 2043. Analyst price targets run from $830 to $1,500, reflecting genuine disagreement about how large and enduring this franchise will be.